IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 36,000 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $179.28, for a total value of $6,454,080.00. Following the transaction, the chairman now directly owns 1,077,112 shares of the company’s stock, valued at approximately $193,104,639.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
IDEXX Laboratories, Inc. (NASDAQ IDXX) traded up $2.87 during trading hours on Wednesday, hitting $178.26. The stock had a trading volume of 1,000,269 shares, compared to its average volume of 620,773. The company has a market capitalization of $15,550.00, a price-to-earnings ratio of 60.63, a PEG ratio of 2.15 and a beta of 0.58. IDEXX Laboratories, Inc. has a 52 week low of $140.63 and a 52 week high of $198.73. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The business had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. During the same period in the prior year, the company posted $0.58 EPS. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. sell-side analysts forecast that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. D.A. Davidson & CO. lifted its position in IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after purchasing an additional 385 shares during the period. BB&T Investment Services Inc. acquired a new stake in IDEXX Laboratories in the second quarter worth approximately $104,000. Zions Bancorporation acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $162,000. Benjamin F. Edwards & Company Inc. lifted its position in shares of IDEXX Laboratories by 1,000.0% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after acquiring an additional 1,000 shares during the last quarter. Finally, SignalPoint Asset Management LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $200,000. 86.50% of the stock is owned by institutional investors and hedge funds.
A number of research analysts recently weighed in on IDXX shares. Bank of America lifted their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and set a $210.00 price objective on shares of IDEXX Laboratories in a research note on Monday, January 29th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective on the stock in a research note on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Finally, BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company. IDEXX Laboratories has an average rating of “Buy” and an average target price of $194.00.
WARNING: “Insider Selling: IDEXX Laboratories, Inc. (IDXX) Chairman Sells 36,000 Shares of Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/15/idexx-laboratories-inc-idxx-chairman-sells-6454080-00-in-stock.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.